Cite
Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling
MLA
Steven T. Haller, et al. “Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, vol. 5, no. 10, Oct. 2016. EBSCOhost, https://doi.org/10.1161/JAHA.116.004106.
APA
Steven T. Haller, Yanling Yan, Christopher A. Drummond, Joe Xie, Jiang Tian, David J. Kennedy, Victoria Y. Shilova, Zijian Xie, Jiang Liu, Christopher J. Cooper, Deepak Malhotra, Joseph I. Shapiro, Olga V. Fedorova, & Alexei Y. Bagrov. (2016). Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5(10). https://doi.org/10.1161/JAHA.116.004106
Chicago
Steven T. Haller, Yanling Yan, Christopher A. Drummond, Joe Xie, Jiang Tian, David J. Kennedy, Victoria Y. Shilova, et al. 2016. “Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 5 (10). doi:10.1161/JAHA.116.004106.